Transthyretin (TTR) amyloidosis (ATTR), a rare disease caused by the misfolding and aggregation of the TTR protein, has reached an inflection point with two drugs approved to treat the disease this year and multiple drugs in development. Read More
Blue chip biopharma equities closed out the month of November on a high note with the BioWorld Biopharmaceutical index up almost 6 percent, which appeared to have helped erase the memories of a tough October that saw the index fall 10 percent in the wake of a general market correction. Read More
